KORU Medical Schedules Q1 2026 Earnings Call Amid Subcutaneous Infusion Market Growth
Event summary
- KORU Medical Systems (NASDAQ: KRMD) will report Q1 2026 financial results on May 6, 2026.
- Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a corporate update.
- The Freedom Syringe Infusion System, first FDA-cleared in 1994, remains central to KORU's product portfolio.
- Company also supports biopharmaceutical clinical trials with customized infusion solutions.
The big picture
KORU Medical operates in a niche but growing segment of the medical technology industry, focusing on large volume subcutaneous infusion solutions. The company's products are used both by patients for self-administration and by healthcare professionals in ambulatory settings. The upcoming earnings call will provide insights into how KORU is navigating the competitive landscape and capitalizing on the increasing demand for home-based healthcare solutions.
What we're watching
- Revenue Growth
- Whether KORU can sustain its growth trajectory in the subcutaneous infusion market.
- Product Innovation
- How the company's ability to customize its Freedom System for clinical trials will impact its market position.
- Regulatory Environment
- The pace at which regulatory approvals for new subcutaneous infusion technologies could disrupt the market.
Related topics